Dihydropyrimidone inhibitors of calcium channel function

Details Dihydropyrimidone inhibitors of calcium channel function Dihydropyrimidone inhibitors of calcium channel function

2007-01-23

2007-01-23

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S269000, C544S295000, C544S316000

Reexamination Certificate

active

10897215

ABSTRACT:
Compounds having the formula,enantiomers, diastereomers, solvates and salts thereof, where R1, R2, R3, R4, A, X, and J are described herein, are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension.

REFERENCES:
patent: 4675321 (1987-06-01), Baldwin et al.
patent: 4684655 (1987-08-01), Atwal
patent: 4684656 (1987-08-01), Atwal
patent: 4689414 (1987-08-01), Atwal
patent: 4728652 (1988-03-01), Atwal
patent: 4753946 (1988-06-01), Atwal et al.
patent: 4769371 (1988-09-01), Atwal
patent: 4824831 (1989-04-01), Atwal
patent: 4855301 (1989-08-01), Atwal et al.
patent: 5202330 (1993-04-01), Atwal et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5889016 (1999-03-01), Bruce et al.
patent: 5942517 (1999-08-01), Nagarathnam et al.
patent: 6143750 (2000-11-01), Patane et al.
patent: 6172066 (2001-01-01), Nagarathnam et al.
patent: 6207444 (2001-03-01), Sidler et al.
patent: 6228861 (2001-05-01), Nagarathnam et al.
patent: 6245773 (2001-06-01), Wong et al.
patent: 6255315 (2001-07-01), Patane et al.
patent: 6268369 (2001-07-01), Nagarathnam et al.
patent: 6274585 (2001-08-01), Cui et al.
patent: 6387893 (2002-05-01), Evans et al.
patent: 2002/0010186 (2002-01-01), Wong et al.
patent: 2005/0043322 (2005-02-01), Murugesan et al.
patent: 3840380 (1989-06-01), None
patent: 0 204 317 (1986-12-01), None
patent: 0 254 119 (1988-01-01), None
patent: 0 236 902 (1990-12-01), None
patent: 0 237 347 (1991-06-01), None
patent: 0 545 845 (1996-02-01), None
patent: 11-35483 (1999-02-01), None
patent: WO 96/14846 (1996-05-01), None
patent: WO 97/17969 (1997-05-01), None
patent: WO 97/42956 (1997-11-01), None
patent: WO 98/33791 (1998-08-01), None
patent: WO 98/51311 (1998-11-01), None
patent: WO 98/57638 (1998-12-01), None
patent: WO 98/57641 (1998-12-01), None
patent: WO 99/23072 (1999-05-01), None
patent: WO 99/48530 (1999-09-01), None
patent: WO 00/02455 (2000-01-01), None
patent: WO 00/06565 (2000-02-01), None
patent: WO 00/15845 (2000-03-01), None
patent: WO 00/37026 (2000-06-01), None
patent: WO 00/59882 (2000-10-01), None
patent: WO 01/02561 (2001-01-01), None
patent: WO 01/19845 (2001-03-01), None
patent: WO 01/22919 (2001-04-01), None
patent: WO 02/06245 (2002-01-01), None
patent: WO 02/078639 (2002-10-01), None
patent: WO 02/079149 (2002-10-01), None
patent: WO 02/079169 (2002-10-01), None
patent: WO 03/007953 (2003-01-01), None
West, Solid Solutions, Solid state chemistry and its applications, Wiley, New York, pp. 358 and 365, 1988.
Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26, 2001.
Putney, Jr. et al., Mechanisms of capacitative calcium entry, Journal of Cell Science, 114(12), pp. 2223-2229, 2001.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines”, J. Med. Chem., vol. 33, No. 9, pp. 2629-2635 (1990.
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers: 2-Heterosubstituted-4-Aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines”, J. Med. Chem., vol. 33, No. 5, pp. 1510-1515 (1990).
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Orally Effective Antihypertension Agents”, J. Med. Chem., vol. 34, No. 2, pp. 806-811 (1991).
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers 5: Bicyclic Dihydropyrimidines as Potent Mimics of Dihydropyridines”, Bioorganic & Medicinal Chemistry Letters, vol. 1, No. 6, pp. 291-294 (1991).
Atwal, K.S. et al., “Substituted 1,4-Dihydropyrimidines. 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihydropyrimidines”, J. Org. Chem., vol. 54, No. 25, pp. 5898-5907 (1989).
Baylis, C. et al., “Comparison of L-Type and Mixed L- and T-Type Calcium Channel Blockers on Kidney Injury Caused by Deoxycorticosterone-Salt Hypertension in Rats”, American Journal of Kidney Diseases, vol. 38, No. 6, pp. 1292-1297 (2001).
Bhattacharjee, A. et al., “T-Type Calcium Channels Facilitate Insulin Secretion by Enhancing General Excitability in the Insulin-Secreting β-Cell Line, INS-1”, Endocrinology, vol. 138, No. 9, pp. 3735-3740 (1997).
Bilici, D. et al., “Protective Effect of T-Type Calcium Channel Blocker in Histamine-Induced Paw Inflammation in Rat”, Pharmacological Research, vol. 44, No. 6, pp. 527-531 (2001).
Catterall, W.A. et al., “Structure and Regulation of Voltage-Gated Ca2+Channels”, Annu. Rev. Cell Dev. Biol., vol. 16, pp. 521-555 (2000).
Chemin, J. et al., “Specific contribution of human T-type calcium channel isotypes (α1G, α1Hand α1I) to neuronal excitability”, Journal of Physiology, vol. 540, Pt. 1, pp. 3-14 (2002).
Clozel, J.-P. et al., “Voltage-Gated T-Type Ca2+Channels and Heart Failure”, Proceedings of the Association of American Physicians, vol. 111, No. 5, pp. 429-437 (1999).
Dhar, T.G.M. et al., “Design and Synthesis of Novel α1aAdrenoceptor-Selective Antagonists. 2. Approaches To Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine Moiety”, J. Med. Chem., vol. 42, No. 23, pp. 4778-4793 (1999).
Glasser, S.P., “The Relevance of T-Type Calcium Antagonists: A Profile of Mibefradil”, J. Clin. Pharmacol., vol. 38, pp. 659-669 (1998).
Harada, K. et al., “Clinical Efficacy of Efonidipine Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activities—Examination Using Spectral Analysis of Heart Rate/Blood Pressure Variabilities and123l-Metaiodobenzylguanidine Myocardial Scintigraphy”, Circulation Journal, vol. 67, pp. 139-145 (2003).
Hayashi, K. et al., “Effect of Efonidipine and ACE Inhibitors on Proteinuria in Human Hypertension With Renal Impairment”, American Journal of Hypertension, vol. 16, No. 2, pp. 116-122 (2003).
Honda, M. et al., “Divergent renal vasodilator action of L- and T-type calcium antagonistsin vivo”, Journal of Hypertension, vol. 19, No. 11, pp. 2031-2037 (2001).
Karam, H. et al., “Contrasting Effects of Selective T- and L-Type Calcium Channel Blockade on Glomerular Damage in DOCA Hypertensive Rats”, Hypertension, vol. 34, pp. 673-678 (1999).
Kochegarov, A.A., “Therapeutical application of voltage-gated calcium channel modulators”, Expert Opin. Ther. Patents, vol. 12, No. 2, pp. 243-287 (2002).
Lagu, B. et al., “Design and Synthesis of a Novel α1aAdrenoceptor-Selective Antagonists. 3. Approaches To Eliminate Opioid Agonist Metabolites by Using Substituted Phenylpiperazine Side Chains”, J. Med. Chem. vol. 42, No. 23, pp. 4794-4803 (1999).
Mannhold, R., “Medicinal Chemistry of DHP-Like Calcium Antagonists”, Drugs of Today, vol. 30, No. 2, pp. 103-122 (1994).
Mason, R.P. et al., “Antioxidant and Cytoprotective Acitivites of the Calcium Channel Blocker Mibefradil”, Biochemical Pharmacology, vol. 55, pp. 1843-1852 (1998).
Min, J.-Y. et al., “Mibefradil Improves β-Adrenergic Responsiveness and Intracellular Ca2+Handling in Hypertrophied Rat Myocardium”, Exp. Biol. Med., vol. 227, No. 5, pp. 336-344 (2002).
Mulder, P. et al., “Increased Survival After Long-Term Treatment With Mibefradil, a Selective T-Channel Calcium Antagonist, in Heart Failure”, J. Am. Coll. Cardiol., vol. 29, No. 2, pp. 416-421 (1997).
Nagarathnam, D. et al., “Design and Synthesi

Affiliated with

Also associated with

Rating

Dihydropyrimidone inhibitors of calcium channel function does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dihydropyrimidone inhibitors of calcium channel function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyrimidone inhibitors of calcium channel function will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3809883